Related references
Note: Only part of the references are listed.Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
Vanita Noronha et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
Yukio Hosomi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
Jang Ho Cho et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma
Alison Dormieux et al.
EUROPEAN RADIOLOGY (2020)
NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
Makoto Maemondo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Yi-Long Wu et al.
LANCET RESPIRATORY MEDICINE (2020)
Bone health in cancer: ESMO Clinical Practice Guidelines
R. Coleman et al.
ANNALS OF ONCOLOGY (2020)
Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial
Anita J. W. M. Brouns et al.
FRONTIERS IN ONCOLOGY (2020)
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
Solange Peters et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival
Takashi Higuchi et al.
TRANSLATIONAL ONCOLOGY (2020)
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases
Marta Lagana et al.
FRONTIERS IN ONCOLOGY (2020)
Bone metastases from lung cancer: A paradigm for multidisciplinary onco-rheumatology management
Cyrille B. Confavreux et al.
JOINT BONE SPINE (2019)
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito et al.
LANCET ONCOLOGY (2019)
Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations
Linpeng Zheng et al.
ONCOLOGIST (2019)
Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor-treated patients with non-small cell lung cancer exhibiting bone metastasis
Xiaoxian Cui et al.
ONCOLOGY LETTERS (2019)
Osimertinib in Patients With T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up From a Pooled Analysis of 2 Phase 2 Studies
Myung-Ju Ahn et al.
CANCER (2019)
Bone metastases and skeletal-related events: incidence and prognosis according to histological subtype of lung cancer
Gustavo T. Silva et al.
FUTURE ONCOLOGY (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
Tony S. Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer
C. C. H. J. Kuijpers et al.
LUNG CANCER (2018)
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort
Isamu Okamoto et al.
LUNG CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.
Noboru Yamamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
Sung Won Lim et al.
LUNG CANCER (2018)
Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
J. Remon et al.
CANCER TREATMENT REVIEWS (2018)
Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China
Hongwei Li et al.
CLINICAL & EXPERIMENTAL METASTASIS (2017)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Nasser Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer
Shu-Mei Huang et al.
ONCOTARGET (2017)
Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
Guowei Zhang et al.
SCIENTIFIC REPORTS (2017)
Bisphosphonates for advanced prostate cancer
Sascha Macherey et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Bisphosphonates and other bone agents for breast cancer
B. O'Carrigan et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan
Jian Guan et al.
MEDICAL ONCOLOGY (2016)
Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
Matjaz Zwitter et al.
CANCER BIOLOGY & THERAPY (2016)
Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials
Nathalie LeVasseur et al.
CANCER TREATMENT REVIEWS (2016)
Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies
Shinji Atagi et al.
FUTURE ONCOLOGY (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss et al.
LANCET ONCOLOGY (2016)
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer The ASPIRATION Study
Keunchil Park et al.
JAMA ONCOLOGY (2016)
A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation
Satoshi Hirano et al.
CHINESE CLINICAL ONCOLOGY (2016)
Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options
Benjamin A. Gartrell et al.
EUROPEAN UROLOGY (2015)
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation
Naruo Yoshimura et al.
LUNG CANCER (2015)
Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis
Daichi Fujimoto et al.
CLINICAL & EXPERIMENTAL METASTASIS (2014)
EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases?
L. E. L. Hendriks et al.
LUNG CANCER (2014)
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression
Noemi Reguart et al.
LUNG CANCER (2014)
Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer
May Hagiwara et al.
SUPPORTIVE CARE IN CANCER (2014)
Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems
Gerry Oster et al.
SUPPORTIVE CARE IN CANCER (2014)
Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies
Chiara D'Antonio et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
Matjaz Zwitter et al.
RADIOLOGY AND ONCOLOGY (2014)
Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed
Naruo Yoshimura et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome
Gerald S. M. A. Kerner et al.
PLOS ONE (2013)
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
Robert C. Doebele et al.
CANCER (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
L. V. Sequist et al.
ANNALS OF ONCOLOGY (2011)
Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells
John Wen-Cheng Chang et al.
CANCER LETTERS (2009)
First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy
Noriaki Sunaga et al.
LUNG CANCER (2007)
The PICO strategy for the research question construction and evidence search
Cristina Mamedio da Costa Santos et al.
REVISTA LATINO-AMERICANA DE ENFERMAGEM (2007)
Share Paper
